What is a systematic, organized approach to treating hypertension, including lifestyle modifications and pharmacologic therapy?

Treatment of Hypertension: A Systematic Approach

Diagnostic Confirmation and Initial Assessment

Start all patients with confirmed hypertension (BP ≥140/90 mmHg) on simultaneous lifestyle modifications AND pharmacological therapy immediately 1.

• Confirm hypertension using out-of-office BP measurements (home BP ≥135/85 mmHg or 24-hour ambulatory BP ≥130/80 mmHg) before initiating treatment 1, 2.
• Measure BP in both arms at the first visit and use the arm with higher values for subsequent measurements 3.
• Calculate 10-year cardiovascular risk using validated tools to guide intensity of therapy 3.
• Screen for secondary causes including primary aldosteronism (measure renin and aldosterone in all confirmed hypertensive patients), renal artery stenosis, obstructive sleep apnea, and pheochromocytoma 3, 2.
• Obtain baseline laboratory tests: serum creatinine, eGFR, potassium, sodium, fasting lipid profile, fasting glucose or HbA1c, and urinary albumin-to-creatinine ratio 3, 4.

Blood Pressure Targets

Target BP <130/80 mmHg for most adults, with systolic BP optimally in the 120-129 mmHg range 3, 4, 5.

• For adults ≥65 years: target systolic BP <130 mmHg 6.
• For patients with diabetes: target <130/80 mmHg 3.
• For patients with chronic kidney disease: target <140/90 mmHg (non-diabetic) or <130/80 mmHg (diabetic) 3.
• Achieve target BP within 3 months of treatment initiation 1, 2.

Lifestyle Modifications (Mandatory for All Patients)

Implement all lifestyle interventions concurrently with pharmacotherapy, as they provide additive BP reduction of 10-20 mmHg 2, 6.

• Dietary changes: Adopt DASH-style diet with 8-10 servings of fruits/vegetables daily, 2-3 servings of low-fat dairy, and Mediterranean dietary pattern 3, 4.
• Sodium restriction: Reduce intake to <2,300 mg/day (ideally <2,000 mg/day) 3, 2, 4.
• Potassium supplementation: Increase dietary potassium through food sources 4, 6.
• Weight management: Target BMI 20-25 kg/m² and waist circumference <94 cm for men 4, 6.
• Physical activity: ≥150 minutes of moderate-intensity aerobic exercise weekly plus resistance training 4, 6.
• Alcohol limitation: <100 g pure alcohol per week, with preference for abstinence 4, 6.
• Smoking cessation: Complete cessation with lifelong abstinence 3, 4.

Pharmacological Treatment Algorithm

Step 1: Initial Therapy (BP ≥140/90 mmHg)

Start with two-drug combination therapy using a single-pill combination (SPC) as first-line treatment 1, 5.

• Preferred combination: RAS blocker (ACE inhibitor OR ARB) + dihydropyridine calcium channel blocker (CCB) 1, 3.
• Alternative combination: RAS blocker + thiazide/thiazide-like diuretic 1.
• Specific drug examples:
  • Telmisartan 40-80 mg + amlodipine 5-10 mg 4
  • Enalapril 10-20 mg + amlodipine 5-10 mg 6
  • Candesartan 16-32 mg + hydrochlorothiazide 12.5-25 mg 6

Exceptions to dual therapy: Consider monotherapy only for patients ≥85 years, those with symptomatic orthostatic hypotension, moderate-to-severe frailty, or elevated BP (120-139/70-89 mmHg) with specific indications 1.

Step 2: Optimize Diuretic Component (If BP Not Controlled)

Before adding a third agent, optimize the diuretic dose and consider switching to a thiazide-like diuretic 2.

• Increase hydrochlorothiazide from 12.5 mg to 25 mg daily 2.
• Preferred switch: Replace hydrochlorothiazide with chlorthalidone 12.5-25 mg daily or indapamide, due to longer duration of action and superior outcomes data 1, 2, 6.
• Reassess BP within 2-4 weeks after optimization 2.

Step 3: Triple Therapy (BP Not Controlled on Two Drugs)

Escalate to three-drug combination: RAS blocker + dihydropyridine CCB + thiazide/thiazide-like diuretic, preferably as a single-pill combination 1, 3.

• Ensure all three medications are at optimal doses before proceeding to step 4 2.
• Monitor serum creatinine, eGFR, and potassium 7-14 days after any dose change 3, 4.

Step 4: Resistant Hypertension (BP Not Controlled on Three Drugs)

Add spironolactone 25 mg daily as the fourth agent, provided serum potassium <4.5 mmol/L and eGFR >45 mL/min/1.73m² 1, 2.

• Critical prerequisite: Verify medication adherence (most common cause of apparent resistance) and confirm BP elevation with home monitoring before adding fourth agent 2.
• Review for substance/drug-induced hypertension: NSAIDs, decongestants, oral contraceptives, stimulants, excessive alcohol, licorice 2.
• Monitor potassium and creatinine closely within 1-4 weeks after spironolactone initiation, as hyperkalemia risk is significant when combined with ACE inhibitors or ARBs 2.

Alternative fourth-line agents (if spironolactone contraindicated or not tolerated): eplerenone, beta-blocker (if not already indicated), centrally acting agent (e.g., clonidine), alpha-blocker (e.g., doxazosin), or amiloride 1, 2.

Step 5: Refractory Hypertension (BP Not Controlled on Four or More Drugs)

Refer to hypertension specialist if BP remains ≥160/100 mmHg despite four-drug therapy at optimal doses 2.

• Refractory hypertension is defined as failure to control BP despite ≥5 antihypertensive agents including a long-acting thiazide-like diuretic and mineralocorticoid receptor antagonist 1.
• Intensify screening for secondary causes of hypertension 2.

Critical Monitoring and Follow-Up

See patients every 1-3 months until BP is controlled, then monitor annually once stable 1, 3, 4.

• Measure BP at every clinical encounter 4.
• Promote home BP monitoring to detect loss of control between visits and differentiate white-coat or masked hypertension 2, 4.
• Perform annual metabolic panel (creatinine, eGFR, potassium, sodium), lipid profile, fasting glucose/HbA1c, and microalbuminuria screening 3, 4.
• Monitor for target-organ damage: left ventricular hypertrophy, microalbuminuria, retinopathy 4.

Medication Adherence Strategies

Instruct patients to take antihypertensive medication at the same time each day to foster habit formation 4.

• Counsel that lifelong antihypertensive therapy is necessary even when BP appears well-controlled, to prevent rebound hypertension 4.
• Use single-pill combinations to improve adherence 1.
• If lifestyle changes are effective in BP lowering, pharmacological treatments may subsequently be down-titrated or stopped as appropriate 1.

Common Pitfalls to Avoid

• Never combine two RAS blockers (ACE inhibitor + ARB), as this increases adverse events without additional benefit 1, 2.
• Do not add a beta-blocker as the fourth agent unless there are compelling indications (e.g., heart failure, post-MI, atrial fibrillation) 2.
• Do not discontinue or reduce medication solely because office BP is well-controlled; verify with home monitoring 4.
• Avoid focusing exclusively on BP; ensure comprehensive cardiovascular risk reduction including lipid management (initiate statin if LDL-C >100 mg/dL), glucose control, and lifestyle interventions 4.
• Never neglect renal function and potassium monitoring in patients on RAS blockers or mineralocorticoid receptor antagonists, even when asymptomatic 4.
• Do not assume office BP reflects 24-hour control; encourage home monitoring to verify sustained control 2, 4.

Special Populations

• Elevated BP (120-139/70-89 mmHg) with low CVD risk (<10% 10-year risk): Lifestyle modifications only 1.
• Elevated BP with high CVD risk (≥10% 10-year risk) or high-risk conditions (established CVD, diabetes, CKD, familial hypercholesterolemia, hypertension-mediated organ damage): Initiate pharmacotherapy plus lifestyle modifications 1.
• Patients ≥85 years: Consider monotherapy initially, with careful monitoring for orthostatic hypotension 1.